Cargando…
Arsenic trioxide rewires mantle cell lymphoma response to bortezomib
Although most of the mantle cell lymphoma (MCL) patients initially responded well to bortezomib (BTZ), the dose-dependent toxicities have greatly limited the application of BTZ to MCL. To investigate the efficacy and mechanism of arsenic trioxide (ATO) with BTZ in inducing apoptosis of MCL cells, tw...
Autores principales: | Zhao, Ling-Ling, Liu, Yuan-Fang, Peng, Li-Jun, Fei, Ai-Mei, Cui, Wen, Miao, Sheng-Chao, Hermine, Olivier, Gressin, Remy, Khochbin, Saadi, Chen, Sai-Juan, Wang, Jin, Mi, Jian-Qing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674002/ https://www.ncbi.nlm.nih.gov/pubmed/26310857 http://dx.doi.org/10.1002/cam4.511 |
Ejemplares similares
-
A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide
por: Kulkarni, Uday, et al.
Publicado: (2020) -
Induction of autophagy and autophagy‐dependent apoptosis in diffuse large B‐cell lymphoma by a new antimalarial artemisinin derivative, SM1044
por: Cheng, Chunyan, et al.
Publicado: (2017) -
Combination of arsenic trioxide and Dasatinib: a new strategy to treat Philadelphia chromosome‐positive acute lymphoblastic leukaemia
por: Wang, Tao, et al.
Publicado: (2017) -
Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib‐based combination therapy: A real‐world experience of off‐label ibrutinib use
por: Chen, Feili, et al.
Publicado: (2020) -
Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes
por: Vallumsetla, Nishanth, et al.
Publicado: (2015)